<DOC>
	<DOCNO>NCT00128583</DOCNO>
	<brief_summary>RATIONALE : Vaccines make tumor cell may help body build effective immune response kill tumor cell . PURPOSE : This phase II trial study vaccine therapy see well work treat patient malignant melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Malignant Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine response patient in-transit cutaneous malignant melanoma treat active immunotherapy comprise polyvalent melanoma vaccine ( Canvaxin™ ) . OUTLINE : This open-label , multicenter study . Patients receive polyvalent melanoma vaccine ( Canvaxin™ ) subcutaneously armpit groin area every 2 week approximately 10 week ( 5 dos ) every 4 week approximately 1 year total treatment ( total 15 dos ) . Patients evidence response week 24 receive treatment . Patients whose disease continue respond completion study treatment eligible new study continue treatment polyvalent melanoma vaccine ( Canvaxin™ ) . After completion study treatment , patient follow 30 day . PROJECTED ACCRUAL : A total 100 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant melanoma At least 1 intransit skin lesion measure 310 mm long diameter PATIENT CHARACTERISTICS : Age 18 80 Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>stage III melanoma</keyword>
</DOC>